Acadia Pharmaceuticals
ACAD
210 hedge funds and large institutions have $3.61B invested in Acadia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 82 increasing their positions, 64 reducing their positions, and 36 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 64
0.38% more ownership
Funds ownership: 96.25% → 96.63% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 36
1% less funds holding
Funds holding: 212 → 210 (-2)
19% less capital invested
Capital invested by funds: $4.44B → $3.61B (-$825M)
30% less call options, than puts
Call options by funds: $24.9M | Put options by funds: $35.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$53.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$45M |
| 3 |
O
OrbiMed
New York
|
+$27.2M |
| 4 |
Janus Henderson Group
London,
|
+$26.3M |
| 5 |
Morgan Stanley
New York
|
+$17.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIG
Senator Investment Group
New York
|
-$54.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40.7M |
| 3 |
EM
Elliott Management
New York
|
-$40M |
| 4 |
Goldman Sachs
New York
|
-$20.1M |
| 5 |
PC
PointState Capital
New York
|
-$11.5M |
ACAD Hedge Fund Activity: Q4 2017 in Review
210 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2017, worth a combined $3.61B — down 19% from $4.44B a quarter earlier.
Fund positioning in ACAD was balanced in Q4 2017: 36 funds opened new positions, 36 closed out, 82 added to existing stakes and 64 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $53.4M. The largest seller was Senator Investment Group, exiting entirely with an estimated $54.4M sold.
- 210 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2017, down from 212 in Q3 2017.
- Funds reported $3.61B of Acadia Pharmaceuticals stock for Q4 2017, down 19% quarter-over-quarter.
- 36 funds opened new Acadia Pharmaceuticals positions in Q4 2017 and 36 closed out, a net change of 0 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2017 was Point72 Asset Management, an estimated $53.4M added.
- The largest Acadia Pharmaceuticals seller in Q4 2017 was Senator Investment Group, an estimated $54.4M sold.
Based on aggregated 13F filings for Q4 2017.